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CASE STUDY
A novel mutation in the CDH1 gene  
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Abstract 
Hereditary diffuse gastric cancer (HDGC) is an inherited form of diffuse type gastric cancer. Germline CDH1 mutations 
have been identified in approximately 15–50 % of affected kindred that meet the clinical criteria for HDGC. If any of 
the criteria is met the individual is referred to genetic counseling and CDH1 testing is offered. In this report we present 
the case of a Spanish family with HDGC harboring a novel CDH1 mutation. A 47 year‑old female with a diagnostic of 
gastric adenocarcinoma and some of her relatives were tested. Study of the entire CDH1 gene, including intron–exon 
boundaries, by PCR and sequencing and immunohistochemical determination of the expression of E‑cadherin were 
performed. A novel heterozygous deletion in exon 9 of CDH1 gene (c.1220_1220delC, p.P407Qfs10), was found in the 
proband, one sister and a nephew. It generates a premature stop codon giving rise to a truncated protein that leads 
to a pathogenic variant. Expression of E‑cadherin was absent or frankly reduced in the proband’s tumor but normal in 
tumor cells of great‑uncle. After these results, the sister underwent prophylactic total gastrectomy, and the nephew 
is under annual endoscopic surveillance. Personal or familial history of diffuse gastric cancer, above all at young age, 
should encourage CDH1 genetic testing. In this sense, the review of the criteria and the addition in the last guideline 
of the recommendation: “other families in which genetic testing may also be considered” broadens the number of 
individuals at risk detected. Since there are not reliable methods for early detection, DGC is usually diagnosed at an 
advanced stage and consequently associated with a poorer outcome. Thus, CDH1 mutations detection contributes to 
an improvement in diagnosis and therapeutic intervention.
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Introduction
Gastric cancer (GC) is currently the fifth most common 
cancer being the third leading cause of cancer death 
worldwide, with nearly one million new diagnoses per 
year. More than three-fourths of those individuals die 
from the disease (Black et al. 2014; GLOBOCAN 2012). 
Most of GC cases are sporadic and hereditary cases 
account for only 1–3 % of GCs, this includes hereditary 
diffuse gastric cancer (HDGC) (Monahan and Hopkins 
2016).
HDGC (OMIM #137215) is an autosomal dominant 
genetic predisposition cancer syndrome with high pen-
etrance. Between 25 and 30  % of cases of HDGC are 
caused by mutations in E-cadherin gene (CDH1) (Hal-
lowell et al. 2016; Hansford et al. 2015). This gene maps to 
chromosome 16q22.1, consists of 16 exons and encodes 
the cell-to-cell adhesion protein, E-cadherin (Masciari 
et  al. 2007). To date, more than 180 different germline 
CDH1 mutations have been identified in HDGC fami-
lies in a diverse range of ethnic groups. Mutation carriers 
have a cumulative risk of GC at 80 years of 70 % for men 
and 56 % in women, together with a high probability of 
lobular breast cancer in females (Corso et al. 2014; Hal-
lowell et al. 2016; Hansford et al. 2015). Germline CDH1 
mutations have been identified in approximately 15–50 % 
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of affected kindreds that meet the clinical criteria for 
HDGC. The wide range of this estimate has to do with 
both, the background incidence of gastric cancer and the 
criteria used to define the syndrome. According to the 
new guidelines, defined in 2015, CDH1 testing should 
be considered in patients who meet one of the following 
criteria (including first and second degree relatives): (1) 
2 GC cases regardless of age, at least one confirmed dif-
fuse gastric cancer (DGC); (2) one case of DGC before 
40  years old or (3) personal or family history of DGC 
and LBC, one diagnosed before 50 years old. In addition, 
testing could be considered in families with: (1) Bilat-
eral lobular breast cancer (LBC) or family history of 2 or 
more cases of LBC before 50 years old; (2) A personal of 
family history of cleft lip/palate in a patient with DGC 
or (3) in  situ signet ring cells and/or pagetoid spread of 
signet ring cells (van der Post et al. 2015). Because DGC 
is often asymptomatic until in its advanced stages, the 
diagnosis is often delayed and, as a result, the prognosis 
is poor. Thus, according to current guidelines, prophylac-
tic total gastrectomy (PTG) should be strongly advised in 
asymptomatic carriers of CDH1 pathogenic mutations, 
since this is the only way to completely eradicate their 
risk of GC; furthermore, almost 100 % of performed gas-
trectomies revealed the presence of microscopic cancer 
foci The optimal timing for the surgery is under debate, 
although most procedures are performed between the 
ages of 20 and 30 years, and current guidelines advocate 
this (Monahan and Hopkins 2016, van der Post et  al. 
2015).
In this report, we describe the identification of a 
family in Spain, affected with HDGC, and carrying a 
novel germline truncating mutation in the CDH1 gene 
(c.1220_1220delC, p.P407Qfs10) which presumably leads 
to a non-functional protein.
Case description
Patient
A 47  year-old female had been complaining of asthenia 
and a significant weight loss in the previous 2  months. 
She was smoker (about 20 cigarettes per day) and had 
no underlying diseases such as diabetes or hypertension. 
Test to detect Helicobacter pylori was negative. After gas-
troendoscopy and other explorations, such as computer-
ized axial tomography scan, histological analysis of the 
tumour confirmed the diagnostic of gastric adenocarci-
noma: diffuse adenocarcinoma with signet-ring cells. The 
proband died during the study.
Some of her relatives presented previous history of 
malignant colorectal polyp (one sister), hyperplastic 
gastric polyp (a nephew) or gastric cancer (great-uncle) 
(Fig. 1). Thus, search for CDH1 germline mutations was 
conducted in the patient and in other members of the 
family (three sisters, a great-uncle and a nephew of the 
proband), after genetic counseling and informed consent.
Immunohistochemical analyses
In order to determine the expression level of the protein, 
paraffin tissue samples were subjected to immunohis-
tochemical staining with monoclonal antibody against 
E-cadherin (clone 36B5, Leica Biosystems, UK) in an 
automated Bond system in combination with Bond Poly-
mer Refine Detection (Leica Biosystems, UK) according 
to manufacturer instructions.
CDH1 study
Genomic DNA extraction was carried out from periph-
eral blood by using QIAamp DNA Blood Mini Kit, and 
from paraffin embedded tissue (from proband’s gastric 
biopsy) with QIAamp DNA FFPE Tissue Kit; following 
manufacturer instructions. In the proband, RNA was also 
Fig. 1 Family pedigree. Shaded circles and squares indicate the presence of the familiar mutation in CDH1 gene
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isolated from peripheral blood with QIAamp RNA Blood 
Mini Kit and from tissue using RNeasy FFPE Kit, and 
then stored at −80 °C.
The CDH1 gene was studied by analyzing the entire 
coding sequence, including intron–exon boundaries, by 
PCR and sequencing. The presence of the mutation was 
confirmed at RNA level in the proband material.
Pathogenicity of the new variant was predicted by in 
silico analysis with bioinformatics tools such as sort-
ing intolerant from tolerant (SIFT) and Mutation Taster. 
ExAC browser of Broad Institute, 1000 Genomes data-
base and dbSNP138, as well as, the human gene muta-
tion database (HGMD), Leiden open variation database 
(LOVD) and ClinVar databases were checked to assess 
the presence/absence of detected alterations in variations 
repositories.
Identification of a novel mutation in the CDH1 gene
A novel heterozygous deletion in exon 9 of CDH1 
gene (NM_004360.4:c.1220_1220delC; NM_004360.4 
(CDH1_i001): p.(Pro407Glnfs*10)), has been found in 
the proband and subsequently in other family members. 
This variant was not found in 100 healthy controls and 
it is not present in 1000G, ExAC and dbSNP, pointing 
out that this variant is not common in population. To the 
best of our knowledge this variant has not been previ-
ously described, and it is not included in ClinVar, HGMD 
or LOVD. Variant has been included in ClinVar database 
(SCV000266475). This mutation, generates a premature 
stop codon at position 407 giving rise to a truncated pro-
tein, that leads to a pathogenic variant (Corso et al. 2014). 
The presence of the mutation was corroborated both, 
at DNA and RNA level in peripheral blood. The muta-
tion was not found in 100 control samples. The variant 
was considered pathogenic/disease causing by in silico 
predictors SIFT and Mutation Taster. Furthermore, this 
variation is considered to be pathogenic, according to 
American College of Medical Genetics and Genomics 
(ACMG) interpretation: null variant in a gene where loss 
of function is a known mechanism o disease, absent in 
population databases, protein length changing variant, 
co-segregation with disease in multiple affected family 
members in a gene definitively known to cause the dis-
ease, and patient’s phenotype highly specific for gene 
(Richards et al. 2015).
One of the sisters (subject IV-2), who was found a 
malignant colorectal polyp at the age of 49, presented 
also the deletion, and her son (nephew of the proband; 
(subject V-1)) harboured also the mutation and had been 
previously diagnosed with hyperplastic gastric polyp. 
Neither of the other relatives tested harboured the muta-
tion and they were healthy, but for the great-uncle (sub-
ject III-1) who had been suffered indeterminate-type GC 
and did not present the mutation. There were other rela-
tives which had been suffered hyperplastic colon polyps 
(subjects II-4; III-10), GC (subject II-2; III-2), and other 
kind of cancer (subjects II-3; III-7), but samples were not 
available for this study.
The sister, carrier of the mutation, and asymptomatic at 
the time of this study, underwent PTG. Her son (subject 
V-1), refused the procedure and is under annual endo-
scopic surveillance (recently, hyperplastic gastric polyps 
has been detected).
It was not possible to establish the origin of this muta-
tion with the data collected. It should be necessary to test 
more relatives in order to determine in which point its 
origin is.
Expression of E‑cadherin in the tumour tissue
In the tumor cells of proband’s gastric biopsy, the immu-
nohistochemical expression of E-cadherin was absent or 
frankly reduced. In contrast, normal continuous mem-
branous staining for E-cadherin was evidenced in gastric 
tumor cells of great-uncle (Fig. 2).
Discussion and evaluation
In this paper the identification of a novel mutation in 
the CDH1 gene in a Spanish family diagnosed with GC 
is described. For HDGC, there are established criteria to 
determine whether an individual is at risk of and requires 
genetic testing for the condition. In the last revision, the 
first and second criteria were merged in a new criterion: 
“Two or more GC cases regardless of age, at least one 
confirmed DGC”, in first-degree and second-degree rela-
tives, covering now families for whom detailed pathology 
is incomplete (Fitzgerald et  al. 2010; van der Post et  al. 
2015).
In this way, despite our patient did not fulfill the strict 
criteria for HDGC, due to the young age of diagnosis, the 
histopathological analysis of the tumour (diffuse adeno-
carcinoma with signet-ring cells), and with an E-cadherin 
expression absent, she was tested for CDH1 mutations, 
and once she was found to have a pathogenic mutation, 
genetic testing was offered to some of her relatives. Our 
finding reinforces the addition in the last guideline of the 
recommendation: “other families in which genetic test-
ing may also be considered” that includes a point that our 
patient had met: “in situ signet ring cells and/or paget-
oid spread of signet ring cells” (van der Post et al. 2015). 
According to our findings, personal or familial history of 
DGC, above all at young age, should encourage CDH1 
genetic testing, even without fulfilling HDGC criteria. 
The detection of well known pathogenic mutations in 
sporadic cases of GC that do not meet HDGC criteria 
(Garziera et al. 2013), supports the importance of search-
ing for CDH1 mutations in this type of cancer, not only 
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to better understand the molecular basis underlying the 
disease, but also to improve genetic testing and therefore 
the clinical management of patients and families at risk.
Pathology reports, preferably by an expert GC patholo-
gist, are essential. The pathology of HDGC is unique but 
requires a high level of expertise in order to maximize 
recognition of specific findings. Because of the detection 
of in  situ signet ring cells and/or pagetoid spread of sig-
net ring cells in the stomach is rarely, if ever, seen in spo-
radic cases, and in these cases genetic testing should be 
considered.
First degree relatives of GC patients are known to have 
twofold to threefold increased risk of GC. This shows the 
importance of informing family members about positive 
mutation results, facilitating a faster testing, diagnosis 
and treatment (Garziera et al. 2013; Onitilo et al. 2013). 
The optimal age to screen individuals from affected fami-
lies is unclear. Rare cases of DGC have been reported in 
affected families before the age of 18, but the overall risk 
of cancer before age 20 is very low (<1 %) (Kaurah et al. 
2007; Pharoah et al. 2001). The risk rises to 4 percent by 
age 30 without prophylactic surgery. Most groups agree 
that consideration of genetic testing can begin at the age 
of informed consent (16 or 18 years of age depending on 
the geographic place of residence) (Blair et al. 2006; van 
der Post et al. 2015). However, decisions as to the age at 
which to institute testing should also take into account 
the earliest age of cancer onset in the individual family.
PTG is now strongly recommended for asymptomatic 
CDH1 mutation carriers. Total gastrectomy for these 
patients completely eliminates their risk of GC and is 
truly prophylactic in terms of preventing their death 
from invasive GC. The current consensus is that the pro-
cedure should be discussed and offered to pathogenic 
CDH1 carriers in early adulthood, generally between ages 
20 and 30 and should be carefully considered at an age 
>75. Family phenotype, especially age of onset of clinical 
cancer in probands, should be taken into account. Some 
suggest consideration of total gastrectomy in CDH1 
mutation carriers at an age 5  years younger than the 
youngest family member who developed gastric cancer 
(Cisco et al. 2008). In CDH1 positive patients who deny 
or want to delay the PTG endoscopic surveillance should 
be considered.
According to recent studies, there is a significant differ-
ence between asymptomatic and symptomatic patients 
who undergo prophylactic total gastrectomy. These 
studies demonstrated that asymptomatic patients were 
all cured after the surgery whereas a high percentage of 
symptomatic ones had tumour recurrence or metastasis, 
and 60 % of them died within 2 years (Chen et al. 2013; 
Corso et  al. 2014). In addition, data from over 100 gas-
trectomies for HDGC have high-lighted the majority 
already contain a tiny focus of signet-ring carcinoma or 
the preinvasive lesions.
The mutation found in our family: (NM_004360.4:c. 
1220_1220delC; NM_004360.4(CDH1_i001): p.(Pro407-
Glnfs*10) generates an early stop codon in the protein 
leading to a truncated protein and thus, pathogenic. To 
date, over 180 different germline CDH1 mutations have 
been identified; the majority are pathogenic mutations 
but a number of variants of uncertain significance (VUS) 
have been described (Hansford et al. 2015; van der Post 
et al. 2015). The majority has been single nucleotide sub-
stitutions leading to non-synonymous changes (splice 
site or truncating mutations); less commonly, there are 
insertions or deletions of several base-pairs leading to 
frameshifts with protein truncation. Approximately 
5 % of familial cases are due to large deletions involving 
multiple exons of the gene (Oliveira et al. 2009; Yamada 
et al. 2014). All germline mutations are evenly distributed 
along the gene and lead to functional haploinsufficiency 
of E-cadherin. CDH1 is a tumor suppressor gene, and 
Fig. 2 Immunohistochemical expression of E‑cadherin (IHQx400). a 
Tumor cells of proband gastric biopsy. b Gastric tumor cells of great‑
uncle
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therefore a somatic second hit is required for initiation of 
tumor formation. The trigger and molecular mechanism 
by which the second allele of E-cadherin is inactivated 
appears to be diverse, and includes promoter hypermeth-
ylation, mutation, and loss of heterozygosity. The end 
result is loss of expression of the cell adhesion molecule 
E-cadherin.
Currently, there are not reliable methods for early 
detection, and GC patients have often a poor prognosis 
since it is often detected at advanced states, more aggres-
sive and difficult to treat, being considered not cur-
able (Black et al. 2014; Garziera et al. 2013; Onitilo et al. 
2013). Annual endoscopic surveillance is recommended 
but direct visualization with endoscopy tends to detect 
lesions late in the disease process and multiple random 
endoscopic samples often returns false negatives. Better 
surveillance methods could reduce morbidity by picking 
up target lesions earlier such that they are amenable to 
endoscopic therapies.
Conclusions
In conclusion, although the HDGC is a rare disease and 
its incidence is low, due to the high pathogenicity and 
penetrance importance should be attached to it. The lack 
of a sensitive screening test for HDGC makes its early 
diagnosis challenging. In this sense, the establishment of 
well defined criteria for the detection of families at risk 
is essential. The identification of CDH1 mutation may 
provide valuable information for genetic counseling, as 
well as comprehensive management and confirmatory 
diagnosis of HDGC and GC risk reduction for the as-yet 
unaffected family members.
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